Literature DB >> 33107159

Optical coherence tomography measurements as potential imaging biomarkers for Parkinson's disease: A systematic review and meta-analysis.

Wen-Chuan Zhou1, Jin-Xin Tao2, Jing Li1.   

Abstract

BACKGROUND AND
PURPOSE: Retinal pathological changes may precede or accompany the deterioration of brain tissue in Parkinson's disease (PD). The purpose of this meta-analysis was to assess the usefulness of optical coherence tomography (OCT) measurements as potential imaging biomarkers for PD.
METHODS: PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched for observational studies (published prior to 30 May 2020) comparing the OCT measurements between PD patients and healthy controls (HCs). Our main end-points were peripapillary retinal nerve fiber layer (pRNFL) thickness, macular ganglion cell complex thickness, macular thickness and macular volume. Pooled data were assessed by use of a random-effects model.
RESULTS: A total of 36 observational studies were identified that included 1712 patients with PD (2548 eyes) and 1778 HCs (2646 eyes). Compared with the HC group, the PD group showed a significant reduction in mean pRNFL thickness (weighted mean difference [WMD] -3.51 μm, 95% confidence interval [CI] -4.84, -2.18; p = 0.000), all quadrants at the pRNFL (WMD range -7.65 to -2.44 μm, all p < 0.05), macular fovea thickness (WMD -5.62 μm, 95% CI -7.37, -3.87; p = 0.000), all outer sector thicknesses at the macula (WMD range -4.68 to -4.10 μm, all p < 0.05), macular volume (WMD -0.21 mm3 , 95% CI -0.36, -0.06; p < 0.05) and macular ganglion cell complex thickness (WMD -4.18 μm, 95% CI -6.07, -2.29; p < 0.05).
CONCLUSIONS: Our pooled data confirmed robust associations between retinal OCT measurements and PD, highlighting the usefulness of OCT measurements as potential imaging biomarkers for PD.
© 2020 European Academy of Neurology.

Entities:  

Keywords:  Parkinson's disease; meta-analysis; optical coherence tomography; retina

Year:  2020        PMID: 33107159     DOI: 10.1111/ene.14613

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

Review 1.  An Eye on Movement Disorders.

Authors:  Duncan Wilson; Mark Hallett; Tim Anderson
Journal:  Mov Disord Clin Pract       Date:  2021-08-10

2.  Characterization of retinal function and structure in the MPTP murine model of Parkinson's disease.

Authors:  Katie K N Tran; Vickie H Y Wong; Jeremiah K H Lim; Ali Shahandeh; Anh Hoang; David I Finkelstein; Bang V Bui; Christine T O Nguyen
Journal:  Sci Rep       Date:  2022-05-09       Impact factor: 4.996

3.  Retinal Nerve Fiber Layer Thickness and Associations With Cognitive Impairment in Parkinson's Disease.

Authors:  Zihan Chang; Fen Xie; Hualing Li; Feilan Yuan; Lina Zeng; Lin Shi; Shuzhen Zhu; Xiaohe Lu; Xiaobo Wei; Qing Wang
Journal:  Front Aging Neurosci       Date:  2022-02-10       Impact factor: 5.750

4.  Editorial: Multi-Modal Imaging in Neurological Conditions: Translational Applications.

Authors:  Maria Petracca
Journal:  Front Neurol       Date:  2022-02-15       Impact factor: 4.003

Review 5.  Optical coherence tomography as retinal imaging biomarker of neuroinflammation/neurodegeneration in systemic disorders in adults and children.

Authors:  Stela Vujosevic; M Margarita Parra; M Elizabeth Hartnett; Louise O'Toole; Alessia Nuzzi; Celeste Limoli; Edoardo Villani; Paolo Nucci
Journal:  Eye (Lond)       Date:  2022-04-15       Impact factor: 4.456

6.  The retinal ganglion cell layer reflects neurodegenerative changes in cognitively unimpaired individuals.

Authors:  Alicia López-de-Eguileta; Sara López-García; Carmen Lage; Ana Pozueta; María García-Martínez; Martha Kazimierczak; María Bravo; Juan Irure; Marcos López-Hoyos; Pedro Muñoz-Cacho; Noelia Rodríguez-Perez; Diana Tordesillas-Gutiérrez; Alexander Goikoetxea; Claudia Nebot; Eloy Rodríguez-Rodríguez; Alfonso Casado; Pascual Sánchez-Juan
Journal:  Alzheimers Res Ther       Date:  2022-04-21       Impact factor: 8.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.